Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $18.06 billion. The enterprise value is $17.48 billion.
| Market Cap | 18.06B |
| Enterprise Value | 17.48B |
Important Dates
The last earnings date was Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 65.60 million shares outstanding. The number of shares has increased by 8.51% in one year.
| Current Share Class | 65.60M |
| Shares Outstanding | 65.60M |
| Shares Change (YoY) | +8.51% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 78.16% |
| Float | 65.56M |
Valuation Ratios
The trailing PE ratio is 18.08 and the forward PE ratio is 31.87.
| PE Ratio | 18.08 |
| Forward PE | 31.87 |
| PS Ratio | 13.22 |
| Forward PS | 8.67 |
| PB Ratio | 10.60 |
| P/TBV Ratio | 10.63 |
| P/FCF Ratio | 31.57 |
| P/OCF Ratio | 30.56 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 40.75, with an EV/FCF ratio of 30.55.
| EV / Earnings | 17.55 |
| EV / Sales | 12.79 |
| EV / EBITDA | 40.75 |
| EV / EBIT | 41.35 |
| EV / FCF | 30.55 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.30.
| Current Ratio | 2.89 |
| Quick Ratio | 2.22 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 1.15 |
| Debt / FCF | 0.89 |
| Interest Coverage | 5.18 |
Financial Efficiency
Return on equity (ROE) is 132.20% and return on invested capital (ROIC) is 17.98%.
| Return on Equity (ROE) | 132.20% |
| Return on Assets (ROA) | 12.99% |
| Return on Invested Capital (ROIC) | 17.98% |
| Return on Capital Employed (ROCE) | 19.82% |
| Weighted Average Cost of Capital (WACC) | 7.08% |
| Revenue Per Employee | $1.15M |
| Profits Per Employee | $837,338 |
| Employee Count | 1,189 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 0.31 |
Taxes
| Income Tax | -690.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 242.67 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 74.70 |
| Average Volume (20 Days) | 701,747 |
Short Selling Information
The latest short interest is 3.00 million, so 5.41% of the outstanding shares have been sold short.
| Short Interest | 3.00M |
| Short Previous Month | 3.13M |
| Short % of Shares Out | 5.41% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.24 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $1.37 billion and earned $995.60 million in profits. Earnings per share was $15.23.
| Revenue | 1.37B |
| Gross Profit | 1.26B |
| Operating Income | 422.71M |
| Pretax Income | 305.00M |
| Net Income | 995.60M |
| EBITDA | 428.86M |
| EBIT | 422.71M |
| Earnings Per Share (EPS) | $15.23 |
Balance Sheet
The company has $1.10 billion in cash and $508.52 million in debt, with a net cash position of $586.60 million or $8.94 per share.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 508.52M |
| Net Cash | 586.60M |
| Net Cash Per Share | $8.94 |
| Equity (Book Value) | 1.70B |
| Book Value Per Share | 25.98 |
| Working Capital | 1.18B |
Cash Flow
In the last 12 months, operating cash flow was $591.03 million and capital expenditures -$18.85 million, giving a free cash flow of $572.18 million.
| Operating Cash Flow | 591.03M |
| Capital Expenditures | -18.85M |
| Depreciation & Amortization | 5.97M |
| Net Borrowing | -35.91M |
| Free Cash Flow | 572.18M |
| FCF Per Share | $8.72 |
Margins
Gross margin is 91.93%, with operating and profit margins of 30.94% and 72.88%.
| Gross Margin | 91.93% |
| Operating Margin | 30.94% |
| Pretax Margin | 22.33% |
| Profit Margin | 72.88% |
| EBITDA Margin | 31.39% |
| EBIT Margin | 30.94% |
| FCF Margin | 43.14% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.51% |
| Shareholder Yield | -8.51% |
| Earnings Yield | 5.53% |
| FCF Yield | 3.17% |
Analyst Forecast
The average price target for Ascendis Pharma is $308.20, which is 11.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $308.20 |
| Price Target Difference | 11.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 52.08% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 9.26 and a Piotroski F-Score of 7.
| Altman Z-Score | 9.26 |
| Piotroski F-Score | 7 |